The Presenilin-1 ΔE9 Mutation Results in Reduced γ-Secretase Activity, but Not Total Loss of PS1 Function, in Isogenic Human Stem Cells  by Woodruff, Grace et al.
Cell Reports
ArticleThe Presenilin-1 DE9 Mutation Results in Reduced
g-Secretase Activity, but Not Total Loss
of PS1 Function, in Isogenic Human Stem Cells
Grace Woodruff,1,4 Jessica E. Young,1,4 Fernando J. Martinez,1 Floyd Buen,1 Athurva Gore,3 Jennifer Kinaga,1 Zhe Li,3
Shauna H. Yuan,2 Kun Zhang,3 and Lawrence S.B. Goldstein1,2,*
1Department of Cellular and Molecular Medicine, Institute for Genomic Medicine and Institute of Engineering in Medicine, University of
California, San Diego, La Jolla, CA 92093, USA
2Department of Neurosciences, Institute for Genomic Medicine and Institute of Engineering in Medicine, University of California, San Diego,
La Jolla, CA 92093, USA
3Department of Bioengineering, Institute for Genomic Medicine and Institute of Engineering in Medicine, University of California, San Diego,
La Jolla, CA 92093, USA
4These authors contributed equally to this work
*Correspondence: lgoldstein@ucsd.edu
http://dx.doi.org/10.1016/j.celrep.2013.10.018
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.SUMMARY
Presenilin 1 (PS1) is the catalytic core of g-secretase,
which cleaves type 1 transmembrane proteins,
including the amyloid precursor protein (APP). PS1
also has g-secretase-independent functions, and
dominant PS1 missense mutations are the most
common cause of familial Alzheimer’s disease
(FAD). Whether PS1 FAD mutations are gain- or
loss-of-function remains controversial, primarily
because most studies have relied on overexpres-
sion in mouse and/or nonneuronal systems. We
used isogenic euploid human induced pluripotent
stem cell lines to generate and study an allelic series
of PS1 mutations, including heterozygous null muta-
tions and homozygous and heterozygous FAD PS1
mutations. Rigorous analysis of this allelic series in
differentiated, purified neurons allowed us to resolve
this controversy and to conclude that FAD PS1muta-
tions, expressed at normal levels in the appropriate
cell type, impair g-secretase activity but do not
disrupt g-secretase-independent functions of PS1.
Thus, FAD PS1 mutations do not act as simple loss
of PS1 function but instead dominantly gain an
activity toxic to some, but not all, PS1 functions.INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
ease that is the most common cause of dementia (Barnes and
Yaffe, 2011). Pathologically, AD is characterized by amyloid pla-
ques consisting of amyloid-beta (Ab) peptides and neurofibrillary974 Cell Reports 5, 974–985, November 27, 2013 ª2013 The Authorstangles composed of hyperphosphorylated tau protein.Whereas
the precise mechanism that causes AD is still under investiga-
tion, key proteins involved in the disease have been identified.
The amyloid precursor protein (APP) and the presenilin genes
(PSEN1 and PSEN2) are all implicated in AD because mutations
in these genes cause dominantly inherited forms of the disease.
Presenilin 1 (PS1) is a multipass transmembrane protein with
multiple biological functions. PS1 undergoes proteolytic pro-
cessing (Thinakaran et al., 1996) to form N- and C-terminal
fragments, which then associate with nicastrin, anterior phar-
ynx-defective 1, and presenilin enhancer 2 to form the g-secre-
tase complex (Edbauer et al., 2003). PS1 functions as the
catalytic core of g-secretase, which cleaves type 1 transmem-
brane proteins, such as APP, Notch, and cadherins. When APP
is cleaved by g-secretase, the Ab fragment, a main component
of senile plaques, is generated. In addition, PS1 has g-secretase-
independent functions, such as maturation and trafficking of
transmembrane proteins, including nicastrin and TrkB (Leem
et al., 2002; Naruse et al., 1998), and downregulation of Wnt
signaling through destabilization of b-catenin (Killick et al.,
2001). More recently, PS1 has also been shown to control
lysosome acidification (Lee et al., 2010; Wolfe et al., 2013).
Mutations in PS1 are the most common cause of FAD, with
over 100 mutations reported to be pathogenic (http://www.
molgen.ua.ac.be/ADMutations; Tanzi and Bertram, 2005). The
dominant amyloid cascade hypothesis posits that familial AD
(FAD) mutations act by increasing the formation of toxic Ab frag-
ments of APP, which are generated by sequential cleavage of
APP by b-secretase and then by g-secretase. The most abun-
dant form (85%) of the Ab peptide contains 40 amino acid res-
idues (Ab40), with a minority (15%) of an alternative species
containing 42 amino acids, Ab42. FAD PS1 mutations generally
increase the proportion of the Ab42 peptide, which is thought
to be the key agent that causes the pathological changes in
FAD (Scheuner et al., 1996). Whether PS1 mutations cause
Table 1. Isogenic iPSC and NPC Lines
Genotype Number of iPSC Clonesa Number of NPC Linesb
WT/WT 6 2
WT/null 1 1
WT/De9 3 2
De9/De9 2 2
De9/null 2 2
aNumber of iPSC clones is the total number of clones that received
the indicated mutations.
bNumber of NPC lines is the number of iPSC clones that were used
to make NPCs.increases in Ab42 and therefore FAD by a gain- or loss-of-
functionmechanism remains controversial. Controversy persists
because virtually all previous studies probing the nature of FAD
PS1 mutations have relied on experimental manipulations that
overexpress PS1 and PS1mutants inmouse and/or nonneuronal
systems (Bentahir et al., 2006; Cha´vez-Gutie´rrez et al., 2012;
Kumar-Singh et al., 2006) or that express mutant forms of PS1
in competition with wild-type forms in cell types that may not
have normal levels of expression of other key genes. For
example, studies of cultured neurons completely lacking PS1
result in near absence of Ab generation suggesting that FAD
PS1 mutations cause a gain of function (De Strooper et al.,
1998). Paradoxically, removal of PS1 from neurons in the adult
mouse brain causes neurodegeneration with aspects of neuro-
pathology similar to that seen in AD (Saura et al., 2004). This
result led to the suggestion that FAD PS1 mutations generate
loss of function of PS1. Similarly, studies using overexpression
of PS1 FADmutations are difficult to interpret, primarily because
overexpression of FAD PS1 mutants do not accurately recapitu-
late normal activity and function of the PS1 protein and because
these studies are done in nonneuronal cell types that do not ex-
press the same amounts of key PS1-interacting proteins as in
neurons. Finally, because mouse models of FAD do not fully
recapitulate the pathologies seen in human patients (Games
et al., 1995; Radde et al., 2008; Ashe and Zahs, 2010), differ-
ences between mouse and human responses to FAD PS1
mutations may be important.
In view of the persistent controversy about the mechanism of
dysfunction caused by FAD PS1 mutations, we set out to test
whether a key and representative FAD PS1 mutation, PS1 De9,
expressed at endogenous levels in human neurons and in an
isogenic genetic background, is similar to or different from
targeted PS1 haploinsufficiency. To achieve this goal, we used
induced pluripotent stem cell (iPSC) technology (Takahashi
et al., 2007), which provides the opportunity to study bona fide
human neuronal cells that express normal levels of neuronal
genes, proteins, and pathways. To compare the effects of spe-
cific mutations in a controlled isogenic genetic background, we
used genome-editing technology with TAL effector nucleases
(TALENs) (Miller et al., 2011; Sander et al., 2011) to generate
and study an allelic series of PS1 mutations, including the FAD
PS1 DE9 mutation. This mutation lacks the PS1 endoproteolysis
site, thus preventing normal PS1 cleavage during maturation,
which facilitates precise quantitative determination of the levelCeof mutant protein in neuronal cells. We compared the phenotypic
consequences of FAD PS1 DE9 mutations to heterozygous
PS1-null mutations, which enabled us to rigorously conclude
that the PS1 DE9 mutant acts as a dominant gain-of-function
mutation by poisoning intact g-secretase enzyme complexes
in human neuronal cells.
RESULTS
Generation of Isogenic iPSC Lines Carrying Different
PS1 Mutations with TALENs
There are several genome-editing methods that have been used
to edit iPSCs, zinc finger nucleases (ZFNs) (Soldner et al., 2011),
TALENs (Hockemeyer et al., 2011), and more recently the
CRISPR/Cas9 system (Mali et al., 2013). We compared both
ZFNs and TALENs (Figure S1) and used TALENs for our
genome-editing strategy. We designed TALENs to target the
PS1 gene in the genome of iPSCs derived from J. Craig Venter
(Gore et al., 2011), whose genome has been sequenced and is
publicly available (Levy et al., 2007). The FAD PS1 DE9 mutation
is a point mutation in the splice acceptor consensus sequence of
intron 8 that causes in-frame skipping of exon 9 (Perez-Tur et al.,
1995). To introduce the DE9 point mutation, we used single-
stranded oligodeoxynucleotides (ssODNs) (Chen et al., 2011)
as the repair template with 60 bp of PS1 homology on either
side. We recovered and screened 192 clonal iPSC lines using
allele-specific PCR to identify lines that had the DE9 mutation.
From 192 candidate lines, 14 lines amplified in the allele-specific
PCR. We cloned and sequenced the PCR products to test
whether candidate lines had incorporated one or two copies of
the DE9 mutation and whether candidate lines had any disrup-
tion of the PS1 gene (i.e., insertions or deletions). This analysis
resulted in recovery of an allelic series of PS1mutations in other-
wise isogenic iPSCs (Table 1; Figure 1A). Although our strategy
was not designed to detect iPSC lines with disruption of the
PS1 locus, we obtained one line with disruption of one PS1 allele
(wild-type [WT]/null) caused by insertion of one nucleotide in
exon 9. This single-nucleotide insertion interrupts the PS1
open reading frame, causes a premature stop codon, and likely
induces nonsense-mediated decay of the PS1 mRNA templated
by this allele (Figure 1B). In total, we generated three lines with
one copy of the DE9 mutation (WT/De9), two lines that were
homozygous for the DE9 mutation (De9/De9), and two lines
with one allele containing the DE9 mutation and the other allele
an insertion in exon 9 that disrupts the PS1 gene (De9/null).
Because g-secretase activity is key to many developmental
pathways (De Strooper et al., 1999), we tested whether intro-
ducing the FAD PS1 DE9 mutation or disrupting one copy of
the PS1 gene affects pluripotency. Staining of iPSC lines with a
typical cell-surface pluripotency marker, Tra-1-81, revealed no
obvious differences between mutant and control lines (Fig-
ure S1F). To test neuronal differentiation, we generated neural
progenitor cells (NPCs) from the isogenic iPSCs. Two NPC lines
per genotype were generated, with the exception of the WT/null
genotype where we only obtained one iPSC line (Table 1). We
used the PA6 coculture differentiation protocol previously used
in our lab (Yuan et al., 2011) along with dual SMAD inhibition
(Chambers et al., 2009) to generate NPCs. After the 12-dayll Reports 5, 974–985, November 27, 2013 ª2013 The Authors 975
Figure 1. PS1 mRNA Is Reduced by Null, but Not FAD PS1 DE9, Mutations
(A) Generation of isogenic iPSC lines harboring PS1-null and DE9 mutations. Insertions of the DE9 mutation or random nucleotide insertions that disrupt the PS1
gene are shown for each allele from each line. The wild-type nucleotide is depicted in blue, and mutations or insertions are in red.
(B) PS1 mRNA levels by qPCR from isogenic NPC lines normalized to TBP. The error bars represent SEM from experiments with technical replicates n = 3.
(C) Western blot for PS1 protein from lysates from each NPC line.
(D) Quantification of PS1 CTF with reference to actin and normalized to the levels in the WT/WT lines. Error bars represent SEM from biological replicates n = 2.
(E) Quantification of full-length (FL)-PS1 with reference to actin and normalized to the levels in the WT/De9 clones. Error bars represent SEM from biological
replicates n = 2.
See also Figure S1.
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Table 2. IPSC and hESC Subclones Have a Low Number of Protein-Coding Mutations
Cell Line and Subclone Unique Mutationsa Chromosome Gene Protein Changeb Mutation Typec Predictiond
iPSC-CVB 1.7 0 N/A N/A N/A N/A N/A
iPSC-CVB 1.8 0 N/A N/A N/A N/A N/A
iPSC-CVB 1.9 3 2,2,8 ACSL3, CCDC108, DKK4 P129S nonsyn tolerated
V398F nonsyn damaging
C166C syn N/A
iPSC-CVI 1.13 0 N/A N/A N/A N/A N/A
iPSC-CVI 1.14 0 N/A N/A N/A N/A N/A
iPSC-CVI 1.15 1 2 WDR33 P587S nonsyn tolerated
hESC-Hues9 1.7 0 N/A N/A N/A N/A N/A
hESC-Hues9 1.8 0 N/A N/A N/A N/A N/A
hESC-Hues9 1.9 1 8 POTEA M299R nonsyn damaging
aNumber of mutations unique to this cell line compared to the parental iPSC or HUES cell lines.
bIndicates whether the detected mutation will change amino acids in the protein.
cIndicates whether the mutation is synonymous or nonsynonymous.
dIndicates whether the mutation is predicted to be damaging to the protein or tolerated.differentiation period, we used fluorescence-activated cell
sorting (FACS) to purify the NPCs (Yuan et al., 2011) to remove
undifferentiated cells and contaminants. We found no significant
differences in the percentage of NPCs marked by cell surface
markers between the different genotypes (Figure S2A). All NPC
lines we recovered exhibited typical morphology and stained
positive for the NPC marker, nestin (Figure S3E).
TALEN-Targeted iPSC Lines Harbor Few New Protein-
Coding Mutations
Recent studies suggest that reprogrammed iPSC lines can
accumulate elevated frequencies of genetic and epigenetic
changes potentially owing to reprogramming and subsequent
selection during culture and expansion (Hussein et al., 2011;
Gore et al., 2011; Lister et al., 2011). Similarly, a concern with us-
ing genome-editing strategies, such as TALENs or ZFNs, is the
occurrence of off-target effects, in particular double-stranded
breaks (DSBs), which may generate insertions or deletions in
protein-coding regions other than those intended for targeting.
Because targeted iPSCs were subcloned after genome-editing
with the TALENs in order to generate clonal cell lines, detecting
mutations due to off-target genome editing is complicated by the
potential mutational effects of the subcloning process itself.
To address these concerns, we performed whole-exome
sequencing on our TALEN-modified iPSC lines and the parent
iPSC line and compared the resultant mutational load to that
found between nonmodified iPSC subclones and human embry-
onic stem cell (hESC) subclones and their iPSC and hESC parent
population. We generated three single-cell subcloned lines each
for two iPSC lines (CVB and CVI) and one hESC line (Hues 9). We
analyzed the mutational load of the protein-coding regions of the
genome by performing exome sequencing on these nine subcl-
oned lines, the six TALEN-edited lines, and the parent iPSC and
hESC lines. We observed a very low frequency of protein-coding
mutations (zero to three) in each of the subcloned lines. Addition-
ally, the number of acquired mutations did not differ between the
iPSC and hESC lines. The mutational load found in each of the
nonmodified iPSC and hESC subclones (Table 2) whenCecompared to their mixed parent population was statistically
very similar to the mutational load found in the TALEN-edited
subclones (Table 3) when compared to their mixed parent pop-
ulation (p = 0.13), indicating that TALEN-based genome editing
does not introduce an additional point mutational load over sub-
cloning. Additionally, the edited subclones did not possess a
detectable increase in indel count, indicating that insertions
and deletions due to off-target DSBs did not seem to occur.
Furthermore, the edited subclones did not possess any chromo-
some-level shifts in allele ratios at known SNP sites, indicating
that the edited lines are not aneuploid. Taken together, these
findings have led us to conclude that subcloning of iPSCs is
not inherently highly mutagenic and that modification with
TALENs is unlikely to cause any significant off-target effects.
Interestingly, recent work from Ding et al. (2013) reports
TALEN modification of Hues1 hESCs. In this paper, TALEN-
modified subclones also demonstrated a low number of off-
target effects as analyzed by whole-exome and whole-genome
sequencing. However, across the subclones, this group found
24 single-nucleotide variants in coding regions, approximately
ten times more than we found in our experiment. The reason
for this difference is puzzling but could possibly be due to differ-
ences in the number of passages the clones underwent prior to
subcloning, differences in the maintenance of the cells (i.e.,
feeders versus feeder-free conditions), or differences inherent
to the particular cell line used. One possibility to circumvent
this discrepancy and ensure truly isogenic cell lines would be
to first subclone iPSCs or hESCs prior to genome-editing with
TALENs.
PS1mRNA Is Substantially Reduced by Null, but Not FAD
DE9 PS1, Mutations
To test whether the TALEN-induced mutations had the expected
molecular effects on PS1 mRNA abundance, we harvested RNA
from NPCs of each PS1 genotype and performed quantitative
RT-PCR analysis. We found that the WT/null line exhibited
decreased PS1 mRNA to 50% of normal (Figure 1B), which
confirmed that the nucleotide insertion in exon 9 results in thell Reports 5, 974–985, November 27, 2013 ª2013 The Authors 977
Table 3. TALEN-Targeted iPSC Lines Have a Low Number of Off-Target Mutations
Genotype Unique Mutationsa Chromosome Gene Protein Changeb Mutation Typec Predictiond
WT/WT 0 N/A N/A N/A N/A N/A
WT/De9 1 8 CSMD1 I2038I syn tolerated
WT/De9 3 4,14,19 SYNE2 E795E syn tolerated
ZNF225 V4668I nonsyn tolerated
PDIA3 G466V nonsyn damaging
De9/De9 1 17 STAT3 R278H nonsyn tolerated
De9/De9 2 5 NUP155 S58Y nonsyn tolerated
PCDH-GA10 A606S nonsyn tolerated
De9/De9 2 5 PCDH-GA10 A606S nonsyn tolerated
De9/null 1 15 PDIA3 S169S syn tolerated
aNumber of mutations unique to this cell line compared to the parental iPSC or HUES cell lines.
bIndicates whether the detected mutation will change amino acids in the protein.
cIndicates whether the mutation is a synonymous or nonsynonymous mutation.
dIndicates whether the mutation is predicted to be damaging to the protein or tolerated.loss of PS1mRNA, likely due to nonsense-mediated decay of the
PS1 message. We also observed that the WT/DE9 lines and the
DE9/DE9 lines did not significantly differ from WT/WT lines for
PS1 mRNA, whereas DE9/null had 50% of normal levels
of PS1 mRNA (Figure 1B). To evaluate PS1 mutant effects
on PS1 protein abundance, we took advantage of the finding
that PS1 undergoes endoproteolysis to generate a 26 to 27 kDa
N-terminal fragment and a 16 to 17 kDa C-terminal fragment
(Thinakaran et al., 1996). Part of the endoproteolysis site is in
exon 9 of PS1, and thus, an important feature of theDE9mutation
is that the endoproteolysis site is destroyed. Therefore, lines con-
taining one copy of DE9 are predicted to generate 50% of the
cleaved product and 50% of the full-length (44 kDa), whereas
cells containing two copies of DE9 should not generate any of
the cleaved product. Western blot analysis using a C-terminal
antibody (Figures 2C–2E) revealed that these lines all behaved
as predicted withWT/DE9 producing 50%of the uncleaved frag-
ment, DE9/DE9 producing 100% of the uncleaved fragment, and
DE9/null producing only uncleaved fragment but at 50% the level
of DE9/DE9. To further confirm that the null mutations were
indeed a true null allele and not a truncated protein with residual
function, we also performed a western blot with an N-terminal
antibody (Figures S1G–S1I). Using an N-terminal antibody, we
also observed significantly decreased protein from cell lines
harboring null PS1 alleles. Thus, basedonPS1mRNAandprotein
production, we concluded that PS1 mutants induced in isogenic
iPSC lines generated the expected effects onPS1mRNAexpres-
sion, protein production, and endoproteolysis.
The PS1 DE9 Mutation Increases the Ab42/Ab40 Ratio
in Human Neurons by Decreasing Ab40
APP normally undergoes several proteolytic processing events
to generate a collection of soluble APP fragments, including
the APP intracellular domain and Ab peptides. Ab peptides are
generated when APP first undergoes cleavage by b-secretase
and then by cleavage with g-secretase. FAD mutations in APP,
PS1, and PS2 have been shown to alter processing of Ab, with
most mutations reported to increase the Ab42/Ab40 ratio when
expressed under a variety of conditions (Qiang et al., 2011;978 Cell Reports 5, 974–985, November 27, 2013 ª2013 The AuthorsKumar-Singh et al., 2006). Because APP processing in human
neurons that generate Ab peptides, in particular Ab42, plays a
key role in AD pathogenesis, we tested for changes in APP pro-
cessing in purified human neurons generated from isogenic
human NPC lines with different PS1 mutations. Purified neurons
were generated by differentiating NPCs for 3 weeks followed by
FACS purification (Yuan et al., 2011). We found no significant dif-
ferences in the percentage of neurons generated between the
different genotypes (Figure S2B). We used a highly sensitive
assay (Israel et al., 2012) to measure Ab38, Ab40, and Ab42 spe-
cies from purified cells and progenitors. We found that cell lines
harboring one copy of DE9 significantly increased the secreted
Ab42/Ab40 ratio by 2-fold, compared to the WT/WT lines (Fig-
ures 2A and 2B). Two copies of DE9 increased the Ab42/Ab40
ratio 3-fold over WT/WT lines, and similarly, DE9/null lines also
tripled the Ab42/Ab40 ratio over WT/WT. Interestingly, WT/null
was not significantly different from WT/WT, demonstrating that
loss of one copy of PS1 does not mimic the DE9 mutation.
We used purified neurons to investigate whether the DE9
mutation increases the Ab42/Ab40 ratio by decreasing Ab40,
increasing Ab42, or both. We observed that the WT/null geno-
type was not significantly different from WT/WT for Ab40 (Fig-
ure 2C). However, all genotypes containing even a single copy
of De9, WT/De9, De9/De9, and De9/null, had significantly
decreased Ab40 (Figure 2C). There were no significant differ-
ences between WT/null and WT/De9 in the amount of Ab42;
however, De9/De9 and De9/null genotypes displayed signifi-
cantly increased amounts of Ab42 (Figure 2D). Therefore, we
conclude that PS1 DE9, expressed at endogenous levels in
human neurons, increases the Ab42/Ab40 ratio by decreasing
Ab40 and increasing Ab42. Additionally, we determined that
loss of one PS1 allele does not significantly alter Ab production
and in particular did not affect the Ab42/Ab40 ratio.
Finally, to test whether PS1 DE9 affects tau phosphorylation,
the other major pathological hallmark of AD, wemeasured phos-
photau at site Thr231, a site that correlates with neurofibrillary
tangle number (Buerger et al., 2006). We did not observe any
significant differences in the ratio of P-tau/T-tau between any
of the PS1 genotypes (Figure S2D).
Figure 2. The PS1 De9 Mutation Increases
the Ab42/Ab40 Ratio by Decreasing Ab40
(A) Secreted Ab42/Ab40 ratio from NPCs. Bars
represent measurements from two NPC lines per
genotype with the exception of the WT/null geno-
type. Error bars represent SEM from six biological
replicates per line.
(B) Secreted Ab42/Ab40 ratio from purified
neurons. Bars represent measurements from two
lines per genotype with the exception of the WT/
null genotype. Error bars represent SEM from six
biological replicates per line.
(C) Secreted Ab40 from purified neurons. Error
bars represent SEM from six biological replicates
per line.
(D) Secreted Ab42 from purified neurons. Error
bars represent SEM from six biological replicates
per line.
See also Figure S2.The PS1 DE9 Mutation Impairs g-Secretase-Dependent
Functions of PS1
To determine directly whether theDE9mutation impairs g-secre-
tase-mediated processing of different protein substrates, we
measured the cleavage of the C-terminal fragments (CTFs) of
APP and N-cadherin, both of which are g-secretase substrates.
Ordinarily, APP first undergoes cleavage by a and b secretases,
which yield a and b CTFs, and then g-secretase further cleaves
the a and b CTFs. Similarly, N-cadherin undergoes an initial pro-
teolytic processing event, which generates a CTF that is also
cleaved by g-secretase. Therefore, if the DE9 mutation impairs
g-secretase activity, we would expect to see an increase in
APP and N-cadherin CTFs. All lines containing at least one
copy of DE9 had significantly increased APP CTFs over WT/
WT (Figures 3A and 3B). We also quantified full-length APP
and observed no significant differences between genotypes
(Figure S2A). This suggests that the DE9 mutation does impair
g-secretase cleavage of APP CTFs. Similarly, we were unable
to detect any N-cadherin CTF for WT/WT, WT/null, and WT/
DE9 genotypes but did observe obviously elevated levels of
CTFs in De9/De9 lines and De9/null lines (Figure 3C). Collec-
tively, these data demonstrate that the DE9 mutation expressed
at endogenous levels in a normal genetic background in human
neurons impairs g-secretase activity.
Previous studies reported that low doses of g-secretase inhib-
itors that moderately impaired g-secretase function increase the
Ab42/Ab40 ratio in a variety of cell types (Sato et al., 2003; Shen
and Kelleher, 2007). Thus, as an additional test of whether the
DE9 mutation decreases g-secretase activity in purified euploid
human neurons, we compared the effects of the DE9mutation to
a low dose of the g-secretase inhibitor, compound E. Similar to
previous reports, we found that a high dose of g-secretase inhib-Cell Reports 5, 974–985, Nitor (200 nM) completely inhibits all Ab
production (data not shown) in all geno-
types. Strikingly, a low dose (5 nM) of
compound E substantially increases the
Ab42/Ab40 ratio in WT/WT, WT/null, and
WT/DE9 neurons, but not in DE9/DE9 or
DE9/null (Figure 3D). Thus, the DE9muta-tion has a similar phenotypic impact on Ab processing as direct
and low-level inhibition of g-secretase. Surprisingly, the DE9
mutation appears to confer resistance to low-dose inhibition of
g-secretase activity by compound E.
The PS1 DE9 Mutation Does Not Impair g-Secretase-
Independent Functions of PS1
To further probe whether the DE9 mutation acts as a loss or gain
of function, we asked whether the DE9mutation interferes with a
g-secretase-independent function of PS1, nicastrin maturation.
Wild-type PS1 has been reported to facilitate nicastrin matura-
tion by acting as a chaperone in early biosynthetic compart-
ments (Leem et al., 2002). Thus, we quantified the relative
amounts of mature and immature nicastrin in purified neurons
with various PS1 genotypes by quantitative western blot (Figures
4A and 4B). We found that the ratio of mature/immature nicastrin
was significantly decreased compared to WT/WT only in cell
lines that harbor a PS1-null mutation (WT/null and De9/null).
There were no significant differences in mature/immature
nicastrin between WT/WT, WT/De9, and De9/De9 genotypes.
This result suggests that the DE9 mutation does not impair all
g-secretase-independent functions of PS1 because it generates
a phenotypic effect that is clearly different from a null allele
(Figure 4C).
DISCUSSION
Based on direct quantitative biochemical comparisons, our re-
sults demonstrate that the phenotypic effects of a proven null
PS1 mutation and an FAD PS1 DE9 mutation are not equivalent
in isogenic euploid-purified human neurons. In addition, the DE9
allele inhibits aspects of g-secretase activity while maintainingovember 27, 2013 ª2013 The Authors 979
Figure 3. The PS1 DE9 Mutation Impairs g-Secretase Activity
(A) Representative western blot of FL-APP and APP CTF.
(B) Quantification of APP CTF with reference to FL-APP and normalized to levels in WT/WT. Each bar represents measurements from three biological replicates.
Error bars represent SEM from three measurements per line.
(C) Western blot of FL N-cadherin and N-cadherin CTF.
(D) Secreted Ab42/Ab40 ratio from purified neurons treated with a g-secretase inhibitor, compound E, at 5 nM. Error bars represent SEM from four biological
replicates per line.
See also Figure S2.normal activity for at least one g-secretase-independent func-
tion, nicastrin maturation. Thus, by using carefully genetically
engineered human cells, this series of experiments reveals that
some, and we propose by extension, all PS1 FAD mutations
are not simple loss-of-function alleles with respect to the
biochemical pathway that generates key phenotypes associated
with the initiation and development of AD.
Previous experiments probing whether the PS1 DE9 mutation
changes the Ab42/Ab40 ratio by increasing Ab42, decreasing
Ab40, or both have been reported multiple times with contradic-
tory results (Cha´vez-Gutie´rrez et al., 2012; Kumar-Singh et al.,
2006). This issue is important because determining how the
FAD PS1 DE9 mutation changes the ratio of Ab species in
euploid human neurons may help to elucidate AD mechanisms
and inform development of effective AD drugs. By taking advan-
tage of the allelic series we generated in a controlled genetic
background in purified human neurons, we were able to deter-
mine that the DE9 mutation increases the Ab42/Ab40 ratio in a
gene-dosage-dependent manner by significantly decreasing
the amount of Ab40 while moderately increasing the amount of
Ab42. Our results are in contrast to some, but not all, previous at-
tempts to clarify this issue. For example, a number of previous
analyses of FAD PS1 mutations used mouse embryonic fibro-
blasts (MEFs) or human embryonic kidney (HEK) cells overex-
pressing PS1 DE9; some experiments incorporated additional
overexpression of human APP and APP mutations. These980 Cell Reports 5, 974–985, November 27, 2013 ª2013 The Authorsstudies are complex to interpret because it is unknown whether
overexpression of PS1 DE9 results in biochemical data accu-
rately representing the normal activity of PS1. An alternative
approach is defined by early studies in C. elegans, which sug-
gested that FAD PS1 mutations encode PS1 proteins with
decreased activity compared toWTPS1 (Shen et al., 1997). Early
studies in HEK cells treated with antisense PS1 RNA showed
increased secretion of Ab42 (Refolo et al., 1999), which also sup-
ported the idea that PS1 mutations are simple loss-of-function.
Later studies from knockout mice suggested that PS1mutations
are gain-of-function because complete loss of PS1 resulted in
severely decreased overall Ab production, unlike PS1mutations.
More recent studies propose that many PS1 mutations have
decreased g-secretase activity (Bentahir et al., 2006; Koch
et al., 2012; Heilig et al., 2010). A common issue among these
studies is that evaluation of Ab production in nonhuman and/or
nonneuronal cells may not be ideal because Ab production and
factors influencing Ab production vary significantly among cell
types (Qiang et al., 2011; Israel et al., 2012) and in comparison
to neurons, which are the primary cell type affected in AD.
Although these differences among cell types and systems might
not have large-scale effects, AD itself and AD phenotypes can be
generated by relatively minor changes in expression of key
genes, e.g., a 50% dosage increase of APP itself is sufficient
to generate severe early onset FAD (Rovelet-Lecrux et al.,
2006). Our system using genetically manipulated isogenic
Figure 4. PS1-Null Mutations, but Not the PS1 De9 Mutation, Impair Nicastrin Maturation
(A) Representative western blot of nicastrin from isogenic lines. Black arrows indicate mature and immature forms of the protein.
(B) Quantification of mature and immature nicastrin. Error bars represent SEM of two biological replicates per line.
(C) Schematic summary of results.iPSC-derived neurons avoids these problems, allows effects of
relatively minor magnitude to be evaluated, and, in principle,
avoids problems of uncontrolled dosage at other key loci.
Here, we report a complete and direct comparison of g-secre-
tase-dependent and -independent functions generated by an
FAD PS1 mutation and a null allele. Strikingly, PS1 haploinsuffi-
ciency had no significant effect on the Ab42/Ab40 ratio or total
levels of Ab40 and Ab42, which again demonstrates that PS1
loss of function and PS1 DE9 are not equivalent with respect to
Ab production and CTF processing. Thus, our finding confirms
that the DE9 mutation is not simply a complete loss of PS1 func-
tion because the DE9 mutation has decreased g-secretase
activity compared to WT PS1 and heterozygous null allele but
has no effect on nicastrinmaturation, ag-secretase-independent
function of PS1. In fact, we found impaired nicastrin maturationCeonly in cell lines that harbored a PS1-null mutation, which further
confirms that PS1DE9maintains at least some normal PS1 func-
tions. Furthermore, we found that PS1 haploinsufficiency had no
detectable effect on APPorN-cadherin cleavage, again suggest-
ing that PS1 haploinsufficiency and PS1 DE9 do not have the
same effect on g-secretase activity. Our findings also suggest
that, under the physiological conditions of our studies and with
respect to the phenotypes measured, g-secretase activity is
available in excess, because loss of one PS1 allele did not signif-
icantly alter g-secretase cleavage of APP or N-cadherin.
In addition to testing how total levels of Ab and the Ab42/Ab40
ratio responded to different PS1 genotypes, we also measured
phosphorylation of tau at Thr231. We did not observe any signif-
icant differences in the ratio of tau phosphorylated at Thr231
relative to total tau when any of our PS1mutants or combinationsll Reports 5, 974–985, November 27, 2013 ª2013 The Authors 981
were compared to WT PS1, even in cell lines that were homozy-
gous for the DE9 mutation and had significantly increased Ab42.
This result is similar to recent studies of neurons made from
IPSCs carrying two different presenilin mutants, PS1 A246E
and PS2 N141I (Yagi et al., 2011) but is in contrast to previous
studies of iPSC-derived neurons from FAD caused by an APP
duplication (Israel et al., 2012) or trisomy 21 (Shi et al., 2012),
both of which reported an increase in the ratio of phosphorylated
tau relative to total tau. An intriguing possibility is that FAD
caused by an extra copy of APP and FAD caused by PS1 muta-
tions differ in the earliest phenotypes and mechanisms by which
they cause disease and thus differ in their induction of abnormal
levels of phosphotau. In this context, there is evidence that
different FAD mutations result in positional and temporal differ-
ences in tau phosphorylation and accumulation. Specifically,
analyses of postmortem AD tissue revealed that different PS1
mutations (Shepherd et al., 2004) affect tau deposition and phos-
phorylation differentially with mutations in PS1 exons 8 and 9
having less hyperphosphorylated tau than mutations in exons 5
and 6. Further studies in iPSC-derived neurons, either with
genome modifications or derived from patients with specific
FAD mutations, will clarify the nature of tau phenotypes in
different FAD mutants.
A major focus of AD therapeutics has been g-secretase inhibi-
tion, which has thus far failed to perform as hoped in clinical trials
(Opar, 2008). In some cases, g-secretase inhibition has even
accelerated cognitive decline (Extance, 2010). Our data suggest
that g-secretase inhibition could worsen patients either by
increasing the proportion of Ab42 or by increasing the amount
of APP CTFs, which have been proposed to play a role in AD
pathogenesis (Rodrigues et al., 2012; Jiang et al., 2010). Interest-
ingly, our recent work in an iPSC-derived human neuronal sys-
tem (Israel et al., 2012) suggested that the b-CTF of APP is toxic
in purified FAD neurons because treatment with a b-secretase in-
hibitor, rather than a g-secretase inhibitor, reduced abnormal
phosphotau levels in these FAD neurons. Given that the FAD
PS1 DE9 mutation decreases the amount of Ab40 in our system
and increases the APP CTFs, it is possible that this class of FAD
mutation confers its toxic properties, in part, by the accumulation
of other pathogenic APP fragments, such as the APP CTF. Thus,
a potentially important therapeutic implication from our work is
that g-secretase modulation that restores the Ab ratios and/or
restores g-secretase function to normal levels or character could
be more beneficial for AD treatment. Future studies character-
izing other PS1 functions that may be affected by drugs and
mutations will also be important for designing AD therapeutics.
A final important implication emerging from the work we report
here concerns the question of whether TALENs introduce signif-
icant off-target mutations in iPSCs. By performing exome
sequencing on genome-edited and subcloned iPSC lines, we
found that the genome-edited lines did not have a significantly
higher number of unique mutations beyond what we observed
in simple iPSC or hESC subcloning experiments. Thus, the intro-
duction of TALENs does not appear to cause major off-target
mutagenic effects. Another recent publication (Ding et al.,
2013) reported that exome and whole-genome sequencing on
TALEN-targeted hESC lines revealed mutations unique to
different subclones, although at an apparently higher frequency982 Cell Reports 5, 974–985, November 27, 2013 ª2013 The Authorsthan we report here, possibly due to inherent differences in the
particular cell line used or in the number of passages the clones
underwent prior to subcloning. Altogether, these data suggest
that it may be impossible to derive completely isogenic cell lines.
However, the relative number of single-nucleotide variants
between TALEN-targeted lines is still apparently less than what
would be observed between different individual human
genomes. Finally, as we report here, the generation of an allelic
series and the analysis of multiple independent lines allows for
careful evaluation of phenotypic effects in a bona fide, euploid
cell-type-representative human model.
EXPERIMENTAL PROCEDURES
iPSC Culture
iPSCs were generated as previously described (Gore et al., 2011; Israel et al.,
2012) following informed consent and Institutional Review Board approval.
iPSCs are cultured on an irradiatedMEF feeder layer generated in-house. Cells
are grown in medium containing knockout (KO) Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco), 10% plasmanate (Talecris Biotherapeutics), 10%
KO Serum Replacement (Gibco), 20 mMGlutaMax (Invitrogen), 20 mM nones-
sential amino acids (Invitrogen), 20 mM Pen/Strep (Invitrogen), and 20 ng/ml
fibroblast growth factor (FGF) (Millipore). Cells were passaged by dissociation
with Accutase (Innovative Cell Technologies).
Isogenic iPSC Generation
iPSCs were pretreated with 10 mM Rock Inhibitor (Ascent Scientific) for 1 hr
prior to nucleofection. Cells were dissociated using Accutase and passed
through a 100 mM filter to obtain single cells. Two million iPSCs were nucleo-
fected using AmaxaHuman StemCell Nucleofector Kit 1 (Lonza), with 7.5 mg of
each TALEN-encoding plasmid, 2 mg of pmaxGFP (Lonza), and 30 mg of
ssODN (Integrated DNA Technologies). Cells were maintained in iPSC culture
conditions with 10 mMRock Inhibitor for 72 hr followed by FACS sorting (FACS
Aria; BD Biosciences) for GFP+ cells. GFP-expressing cells were plated at 13
104 cells per 10 cm plate in the presence of Rock Inhibitor. Thereafter, media
was changed every other day until isolated colonies grew. Isolated colonies
were manually picked and grown in 96-well plates. Once cells were confluent,
cells were split into a duplicate well and grown until confluent, at which point
they were harvested for DNA using DNA QuickExtract (Epicenter). DNA was
amplified using allele-specific primers to detect the DE9 point mutation using
Jump Start PCR Ready Mix (Sigma). Cell lines that amplified using the allele-
specific PCR were then digested with EcoRI to further confirm insertion of
the ssODN. To sequence the PCR products, we cloned them using the Zero
Blunt PCR Cloning Kit (Invitrogen).
Exome Sequencing
Exome sequencing was performed as previously described (Gore et al., 2011).
Briefly, genomic DNA from each sample was sheared and ligated to barcoded
Illumina sequencing adaptors. DNA was then hybridized using the Roche
NimbleGen SeqCap EZ Exome library to capture exomic regions. Exome
regions were captured with streptavidin-coated beads and then PCR-ampli-
fied with Illumina sequencing adaptors. The resulting libraries were sequenced
on an Illumina Genome Analyzer IIx or Illumina Hiseq. Reads were mapped to
the whole genome using Burrows-Wheeler Alignment tool, and a consensus
sequence was generated using the Genome Analysis Toolkit (Broad Institute
best practices). Consensus sequences between the progenitor cell lines and
subcloned cell lines were compared in order to look for candidate novel
mutations. Candidate variants that occurred at locations present in the Single
Nucleotide Polymorphism Database or that showed any presence in the
progenitor line were removed. Identified candidate mutations were validated
by Sanger sequencing.
Statistical Analysis of Mutation Counts
To determine if TALEN modification resulted in an increased off-target point
mutational load, the number of mutations in the TALEN-modified subcloned
iPSC lines was compared to the number of mutations in the unmodified subcl-
oned pluripotent stem cell lines. In order to analyze the potential mutational
load introduced by the TALEN process itself and exclude any normal culture
mutations, the number of mutations acquired after subcloning was analyzed
rather than any overall iPSC mutations acquired due to reprogramming or
postreprogramming culture. Because of the varied culture history of each pro-
genitor line and subclone, it was difficult to construct a hypothetical mutational
distribution for each line. Thus, the nonparametric Mann-Whitney test was
used to compare the median number of mutations in each subclone group.
The test revealed that TALEN-modified and unmodified subclones had a
similar median number of mutations; no significant difference could be deter-
mined (p = 0.13). This indicates that TALEN-modified lines do not acquire any
additional mutational load over that expected during normal culture and
subcloning.
NPC Differentiation, Purification, and Culture
iPSCs were differentiated to NPCs as previously described (Yuan et al., 2011).
Briefly, 1 3 105 iPSCs were seeded onto PA6 cells in PA6 differentiation
medium: Glasgow DMEM, 10% knockout serum replacement, 1 mM sodium
pyruvate, 0.1 mM nonessential amino acids, and 0.1 mM b-mercaptoethanol
(all from Invitrogen). For the first 6 days, media was not changed and also
contained 500 ng/ml Noggin (R&D Systems) and 10 mM SB431542 (Tocris
Bioscience). After the first 6 days, medium was changed every other day until
day 12. On day 12, cells were dissociated and stained with CD184, CD44,
CD271, and CD24 (all from BD Biosciences). CD184+, CD24+, CD44,
CD271 cells were sorted (FACSAria, BD Biosciences). NPC cultures were
cultured on 20 mg/ml poly-L-ornithine- and 5 mg/ml laminin-coated (both
from Sigma) plates in medium containing: DMEM:F12 + Glutamax, 0.53 N2,
0.53 B27 (both from Life Technologies), 13 penicillin/streptomycin, and
20 ng/ml FGF (Millipore). Media was changed every other day.
Neuron Differentiation, Purification, and Culture
NPCswere expanded to 10 cm plates and grown to confluency (3 to 4 days), at
which point FGF was removed from the media. The medium was changed
twice per week, and the cells were differentiated for 21 days. After the
3-week differentiation, neurons were purified as previously described (Yuan
et al., 2011). Briefly, cells were dissociated using Accutase and Accumax
(both from Innovative Cell Technologies) and then stained with CD184,
CD44, and CD24 (all from BD Biosciences). CD184, CD44, CD24+ cells
were sorted (FACSAria; BD Biosciences) and then plated on poly-ornithine/
laminin-coated plates in NPC media + 0.5 mM dbCAMP (Sigma), 20 ng/ml
brain-derived neurotrophic factor, and 20 ng/ml glial cell line-derived neuro-
trophic factor (both from Peprotech).
Gene Expression Analysis
For mRNA expression analysis, total RNA was prepared using RNeasy kit
(QIAGEN). The RNA was DNase treated (Ambion), and first-strand cDNA syn-
thesis was performed with Superscript (Invitrogen). Quantitative PCR (qPCR)
wasdoneonanAppliedBiosystems7300 real-timePCRsystemusingFastStart
Universal SYBRGreenMaster (Roche). Results were quantified using theDDCt
method. PS1 levels were normalized to the housekeeping genes TATA-binding
protein (TBP) or the ribosomal protein RPL27. Primers for PS1 spanned exons 4
and 5. The forward primer sequence is TGACTCTCTGCATGGTGGTGG. The
reverse primer sequence is TCTCTGGCCCACAGTCTCGGT.
AbMeasurements
NPCswere plated at a density of 53 105 in 12-well plates. Media was changed
24 hr after plating and replaced with 0.5 ml of NPC media + FGF. After 48 hr,
media was harvested and stored at 80C and protein was harvested for
normalization purposes. Neurons were plated at density of 1.5 3 105 per
96-well in a 100 ml volume of glial conditioned media. Media was harvested
from purified neurons after 2 weeks. Glial-conditioned medium was made by
putting NPC media onto glia (Lonza) for 24 hr. Ab from the media was
measured with MSD Human (6E10) Abeta3-Plex Kits (Meso Scale Discovery).
For experiments with g-secretase inhibitor, all media was changed on day 3
and replaced with 100 ml of media either with compound E or DMSO (vehicle).
All media was harvested on day 5. Compound E (EMD Chemicals) was used atCeconcentrations of 5 nM and 200 nM. Three to six independent measurements
were made per line. Each NPC line was differentiated twice in independent
experiments for purified neurons.
Gel Electrophoresis and Western Blot
Tissue culture lysates were prepared using radioimmunoprecipitation assay
lysis buffer (Millipore) supplemented with protease (cocktail set I; Calbiochem)
and phosphatase (Halt; Pierce) inhibitors. The bicinchoninic acid assay
(Pierce) was used to estimate the protein content. Equal protein amounts
were separated in MES buffer alongside Novex Sharp prestained markers
(Invitrogen) on NUPAGE 4%–12% Bis-Tris precast gels (Invitrogen) and then
transferred to polyvinylidene fluoride or nitrocellulose (0.45 mm pore size
Immobilon; Millipore). Membranes were blocked in 5% BSA in tris-buffered
saline with 0.1% Tween-20 or Odyssey Blocking Buffer (LI-COR Biosciences).
Primary antibodies (presenilin 1 c-loop 1:1,000, Chemicon; presenilin 1 N-term
1:1,000, Santa Cruz; APP C terminus 1:1,000, Calbiochem; N-cadherin
C terminus 1:1,000, BD Biosciences; nicastrin 1:1,000, Affinity BioReagents;
actin C4 1:100,000, Chemicon; tubulin-alpha DM1A 1:50,000, Sigma) were
prepared in 5%BSA. Fluorescent secondary antibodies (LI-COR Biosciences)
were diluted 1:5,000. LI-COR Biosciences Odyssey infrared imager was used
to measure pixel intensities of bands at detector settings set at the maximum
or one-half unit below saturation. For each protein band, background-
subtracted integrated intensity values were calculated using the Odyssey soft-
ware. Given that absolute integrated intensity values vary for the same
samples on different blots, samples within a blot were plotted relative to
control, and these normalized values were used to average replicates from
separate blots. To show protein bands in the conventional manner with dark
bands on a light background, grayscale images were inverted in the figures.
Horseradish peroxidase-conjugated secondary antibodies (Invitrogen) were
diluted 1:5,000. Blots were developed using ECL Western Blotting Kit (Pierce).
Statistical Methods
All data were analyzed using GraphPad Prism Software (GraphPad).
Statistical analysis comparing different genotypes was performed by Tukey’s
multiple comparison test. Drug responses were compared to controls by
Dunnett’s test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.10.018.
ACKNOWLEDGMENTS
The authors are funded by the California Institute of Regenerative Medicine
(RT2-01927 awarded to L.S.B.G. and RB3-05083 awarded to K.Z.) and the
National Institutes of Health/National Institutes of Aging (R01AG032180).
J.E.Y. is supported by the A.P. Giannini Foundation for Medical Research.
G.W. is supported by an institutional training grant (2T32AG000216-21). The
authors thank Angels Almenar-Queralt for insightful discussion and feedback,
Lauren Fong for helpful input, and Dr. Toni Cathomen (University Medical
Center Freiburg) and Christien Bednarski for kindly providing protocols and
plasmids for performing the episomal assay.
Received: January 18, 2013
Revised: September 6, 2013
Accepted: October 10, 2013
Published: November 14, 2013
REFERENCES
Ashe, K.H., and Zahs, K.R. (2010). Probing the biology of Alzheimer’s disease
in mice. Neuron 66, 631–645.
Barnes, D.E., and Yaffe, K. (2011). The projected effect of risk factor reduction
on Alzheimer’s disease prevalence. Lancet Neurol. 10, 819–828.ll Reports 5, 974–985, November 27, 2013 ª2013 The Authors 983
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horre´, K., Wiltfang, J.,
Esselmann, H., and De Strooper, B. (2006). Presenilin clinical mutations can
affect gamma-secretase activity by different mechanisms. J. Neurochem.
96, 732–742.
Buerger, K., Ewers, M., Pirttila¨, T., Zinkowski, R., Alafuzoff, I., Teipel, S.J.,
DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., and Hampel, H.
(2006). CSF phosphorylated tau protein correlates with neocortical neurofibril-
lary pathology in Alzheimer’s disease. Brain 129, 3035–3041.
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain,
M., and Studer, L. (2009). Highly efficient neural conversion of human
ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27,
275–280.
Cha´vez-Gutie´rrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar,
M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann,
H., et al. (2012). The mechanism of g-Secretase dysfunction in familial Alz-
heimer disease. EMBO J. 31, 2261–2274.
Chen, F., Pruett-Miller, S.M., Huang, Y., Gjoka, M., Duda, K., Taunton, J., Col-
lingwood, T.N., Frodin, M., and Davis, G.D. (2011). High-frequency genome
editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat.
Methods 8, 753–755.
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G.,
Annaert, W., Von Figura, K., and Van Leuven, F. (1998). Deficiency of preseni-
lin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391,
387–390.
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm,
J.S., Schroeter, E.H., Schrijvers, V., Wolfe, M.S., Ray, W.J., et al. (1999). A pre-
senilin-1-dependent gamma-secretase-like protease mediates release of
Notch intracellular domain. Nature 398, 518–522.
Ding, Q., Lee, Y.K., Schaefer, E.A., Peters, D.T., Veres, A., Kim, K., Kuper-
wasser, N., Motola, D.L., Meissner, T.B., Hendriks, W.T., et al. (2013). A TALEN
genome-editing system for generating human stem cell-based disease
models. Cell Stem Cell 12, 238–251.
Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., and Haass, C.
(2003). Reconstitution of gamma-secretase activity. Nat. Cell Biol. 5, 486–488.
Extance, A. (2010). Alzheimer’s failure raises questions about disease-
modifying strategies. Nat. Rev. Drug Discov. 9, 749–751.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Black-
well, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995).
Alzheimer-type neuropathology in transgenic mice overexpressing V717F
beta-amyloid precursor protein. Nature 373, 523–527.
Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J.,
Canto, I., Giorgetti, A., Israel, M.A., Kiskinis, E., et al. (2011). Somatic coding
mutations in human induced pluripotent stem cells. Nature 471, 63–67.
Heilig, E.A., Xia, W., Shen, J., and Kelleher, R.J., 3rd. (2010). A presenilin-1
mutation identified in familial Alzheimer disease with cotton wool plaques
causes a nearly complete loss of gamma-secretase activity. J. Biol. Chem.
285, 22350–22359.
Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost,
G.J., Zhang, L., Santiago, Y., Miller, J.C., et al. (2011). Genetic engineering of
human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731–734.
Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R., Na¨rva¨, E., Ng,
S., Sourour, M., Ha¨ma¨la¨inen, R., Olsson, C., et al. (2011). Copy number varia-
tion and selection during reprogramming to pluripotency. Nature 471, 58–62.
Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan,
M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S., et al. (2012). Probing sporadic
and familial Alzheimer’s disease using induced pluripotent stem cells. Nature
482, 216–220.
Jiang, Y., Mullaney, K.A., Peterhoff, C.M., Che, S., Schmidt, S.D., Boyer-
Boiteau, A., Ginsberg, S.D., Cataldo, A.M., Mathews, P.M., and Nixon, R.A.
(2010). Alzheimer’s-related endosome dysfunction in Down syndrome is
Abeta-independent but requires APP and is reversed by BACE-1 inhibition.
Proc. Natl. Acad. Sci. USA 107, 1630–1635.984 Cell Reports 5, 974–985, November 27, 2013 ª2013 The AuthorsKillick, R., Pollard, C.C., Asuni, A.A., Mudher, A.K., Richardson, J.C., Rupniak,
H.T., Sheppard, P.W., Varndell, I.M., Brion, J.P., Levey, A.I., et al. (2001).
Presenilin 1 independently regulates beta-catenin stability and transcriptional
activity. J. Biol. Chem. 276, 48554–48561.
Koch, P., Tamboli, I.Y., Mertens, J., Wunderlich, P., Ladewig, J., Stu¨ber, K.,
Esselmann, H., Wiltfang, J., Bru¨stle, O., and Walter, J. (2012). Presenilin-1
L166P mutant human pluripotent stem cell-derived neurons exhibit partial
loss of g-secretase activity in endogenous amyloid-b generation. Am. J.
Pathol. 180, 2404–2416.
Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K.,
Corsmit, E., Cruts, M., Dermaut, B., Wang, R., and Van Broeckhoven, C.
(2006). Mean age-of-onset of familial alzheimer disease caused by presenilin
mutations correlates with both increased Abeta42 and decreased Abeta40.
Hum. Mutat. 27, 686–695.
Lee, J.H., Yu, W.H., Kumar, A., Lee, S., Mohan, P.S., Peterhoff, C.M., Wolfe,
D.M., Martinez-Vicente, M., Massey, A.C., Sovak, G., et al. (2010). Lysosomal
proteolysis and autophagy require presenilin 1 and are disrupted by
Alzheimer-related PS1 mutations. Cell 141, 1146–1158.
Leem, J.Y., Vijayan, S., Han, P., Cai, D., Machura, M., Lopes, K.O., Veselits,
M.L., Xu, H., and Thinakaran, G. (2002). Presenilin 1 is required for maturation
and cell surface accumulation of nicastrin. J. Biol. Chem. 277, 19236–19240.
Levy, S., Sutton, G., Ng, P.C., Feuk, L., Halpern, A.L., Walenz, B.P., Axelrod,
N., Huang, J., Kirkness, E.F., Denisov, G., et al. (2007). The diploid genome
sequence of an individual human. PLoS Biol. 5, e254.
Lister, R., Pelizzola,M., Kida, Y.S., Hawkins, R.D., Nery, J.R., Hon, G., Antosie-
wicz-Bourget, J., O’Malley, R., Castanon, R., Klugman, S., et al. (2011).
Hotspots of aberrant epigenomic reprogramming in human induced pluripo-
tent stem cells. Nature 471, 68–73.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E.,
and Church, G.M. (2013). RNA-guided human genome engineering via Cas9.
Science 339, 823–826.
Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F., Meng, X.,
Paschon, D.E., Leung, E., Hinkley, S.J., et al. (2011). A TALE nuclease architec-
ture for efficient genome editing. Nat. Biotechnol. 29, 143–148.
Naruse, S., Thinakaran, G., Luo, J.J., Kusiak, J.W., Tomita, T., Iwatsubo, T.,
Qian, X., Ginty, D.D., Price, D.L., Borchelt, D.R., et al. (1998). Effects of PS1
deficiency onmembrane protein trafficking in neurons. Neuron 21, 1213–1221.
Opar, A. (2008). Mixed results for disease-modification strategies for
Alzheimer’s disease. Nat. Rev. Drug Discov. 7, 717–718.
Perez-Tur, J., Froelich, S., Prihar, G., Crook, R., Baker, M., Duff, K., Wragg, M.,
Busfield, F., Lendon, C., Clark, R.F., et al. (1995). A mutation in Alzheimer’s
disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport
7, 297–301.
Qiang, L., Fujita, R., Yamashita, T., Angulo, S., Rhinn, H., Rhee, D., Doege, C.,
Chau, L., Aubry, L., Vanti, W.B., et al. (2011). Directed conversion of
Alzheimer’s disease patient skin fibroblasts into functional neurons. Cell 146,
359–371.
Radde, R., Duma, C., Goedert, M., and Jucker, M. (2008). The value of incom-
pletemousemodels of Alzheimer’s disease. Eur. J. Nucl. Med.Mol. Imaging 35
(Suppl 1), S70–S74.
Refolo, L.M., Eckman, C., Prada, C.M., Yager, D., Sambamurti, K., Mehta, N.,
Hardy, J., and Younkin, S.G. (1999). Antisense-induced reduction of presenilin
1 expression selectively increases the production of amyloid beta42 in trans-
fected cells. J. Neurochem. 73, 2383–2388.
Rodrigues, E.M., Weissmiller, A.M., and Goldstein, L.S.B. (2012). Enhanced
b-secretase processing alters APP axonal transport and leads to axonal
defects. Hum. Mol. Genet. 21, 4587–4601.
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerrie`re, A.,
Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006).
APP locus duplication causes autosomal dominant early-onset Alzheimer dis-
ease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26.
Sander, J.D., Cade, L., Khayter, C., Reyon, D., Peterson, R.T., Joung, J.K., and
Yeh, J.R. (2011). Targeted gene disruption in somatic zebrafish cells using
engineered TALENs. Nat. Biotechnol. 29, 697–698.
Sato, T., Dohmae, N., Qi, Y., Kakuda, N., Misonou, H., Mitsumori, R.,
Maruyama, H., Koo, E.H., Haass, C., Takio, K., et al. (2003). Potential link
between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of
beta-amyloid precursor protein. J. Biol. Chem. 278, 24294–24301.
Saura, C.A., Choi, S.Y., Beglopoulos, V., Malkani, S., Zhang, D., Shankaranar-
ayana Rao, B.S., Chattarji, S., Kelleher, R.J., 3rd, Kandel, E.R., Duff, K., et al.
(2004). Loss of presenilin function causes impairments of memory and synap-
tic plasticity followed by age-dependent neurodegeneration. Neuron 42,
23–36.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird,
T.D., Hardy, J., Hutton, M., Kukull, W., et al. (1996). Secreted amyloid b-protein
similar to that in the senile plaques of Alzheimer’s disease is increased in vivo
by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s
disease. Nat. Med. 2, 864–870.
Shen, J., and Kelleher, R.J., 3rd. (2007). The presenilin hypothesis of
Alzheimer’s disease: evidence for a loss-of-function pathogenic mechanism.
Proc. Natl. Acad. Sci. USA 104, 403–409.
Shen, J., Bronson, R.T., Chen, D.F., Xia, W., Selkoe, D.J., and Tonegawa, S.
(1997). Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89,
629–639.
Shepherd, C.E., Gregory, G.C., Vickers, J.C., Brooks, W.S., Kwok, J.B.J.,
Schofield, P.R., Kril, J.J., and Halliday, G.M. (2004). Positional effects of
presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol.
Dis. 15, 115–119.CeShi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S.H., and Livesey, F.J.
(2012). A human stem cell model of early Alzheimer’s disease pathology in
Down syndrome. Sci. Transl. Med. 4, 24ra29.
Soldner, F., Laganie`re, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan,
R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S., et al. (2011). Generation
of isogenic pluripotent stem cells differing exclusively at two early onset
Parkinson point mutations. Cell 146, 318–331.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Tanzi, R.E., and Bertram, L. (2005). Twenty years of the Alzheimer’s disease
amyloid hypothesis: a genetic perspective. Cell 120, 545–555.
Thinakaran, G., Borchelt, D.R., Lee, M.K., Slunt, H.H., Spitzer, L., Kim, G.,
Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger,M., et al. (1996). Endopro-
teolysis of presenilin 1 and accumulation of processed derivatives in vivo.
Neuron 17, 181–190.
Wolfe, D.M., Lee, J.H., Kumar, A., Lee, S., Orenstein, S.J., and Nixon, R.A.
(2013). Autophagy failure in Alzheimer’s disease and the role of defective
lysosomal acidification. Eur. J. Neurosci. 37, 1949–1961.
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka,
S., Okano, H., and Suzuki, N. (2011). Modeling familial Alzheimer’s disease
with induced pluripotent stem cells. Hum. Mol. Genet. 20, 4530–4539.
Yuan, S.H., Martin, J., Elia, J., Flippin, J., Paramban, R.I., Hefferan, M.P., Vidal,
J.G., Mu, Y., Killian, R.L., Israel, M.A., et al. (2011). Cell-surface marker signa-
tures for the isolation of neural stem cells, glia and neurons derived from
human pluripotent stem cells. PLoS ONE 6, e17540.ll Reports 5, 974–985, November 27, 2013 ª2013 The Authors 985
